Skip to content
- Badgwell BD, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008;19:577-82.
- Deininger MW, et al. Practical management of patients with chronic myeloid leukaemia receiving imatinib. J Clin Oncol 2003;21:1637-47.
- Eskens FA, et al. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127-39.
- Giantonio BJ. Gastrointestinal perforation and cancer therapy: managing risk to achieve benefit. Onkologie 2005;28:177-8.
- Sandler AB. Nondermatologic adverse events associated with anti-EGFR therapy. Oncology 2006;20(Suppl 2):35-40.
- Van Cutsem E, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009;20:1842-7.
- Postow MA. Managing immune checkpoint-blocking antibody side effects. AM Soc Clin Oncol Educ Book 2015;35:76-83.
- Uslu U, et al. Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab. J Immunother 2015;38(5):212-5.
- Hinds AM. Ipilumimab-induced colitis: a rare but serious side effect. Endoscopy 2014;46(Suppl 1):E308-9.
- Hapani S, et al. Risk of gastrointestinal perforation in patients with bevacizumab: a meta-analysis. Lancet Oncol 2009;10(6):559-68.
- Porta C, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011;47(9):1287-98.
- Chaubet Houdu M, et al. Toxicité digestive des thérapeutiques ciblées. La Lettre du cancérologue n°3-Mars 2013
- Weber J, et al. Toxicities of immunotherapies for the practitioner. J Clin Oncol 2015;33(18):2092-9.